Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  GIMV NV
 2. Date of Event Requiring Statement (Month/Day/Year)
10/03/2006		 3. Issuer Name and Ticker or Trading Symbol
TorreyPines Therapeutics, Inc. [TPTX]
(Last)
(First)
(Middle)
KAREL OOMSSTRAAT 37		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

ANTWERP, C9 B-2018		 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 2,215,883
I
See footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (Right to Buy) 10/03/2006 10/03/2009 Common Stock 412,720 $ 8.32 I See Footnote (2)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
GIMV NV
KAREL OOMSSTRAAT 37
ANTWERP, C9 B-2018		     X    
ADVIESBEHEER GIMV LIFE SCIENCES NV
KAREL OOMSSTRAAT 37
ANTWERP, C9 B-2018		     X    
Biotech Fonds Vlaanderen NV
KAREL OOMSSTRAAT 37
ANTWERP, C9 B-2018		     X    

Signatures

/s/ Dirk Boogmans 10/03/2006
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Received in exchange for shares of TPTX, Inc. common and preferred stock in connection with the Agreement and Plan of Merger and Reorganization entered into by and among the Issuer, its wholly-owned subsidiary and TPTX, Inc. (the "Merger Agreement"). The shares are held as follows: 1,544,403 shares held by GIMV NV; 193,776 shares held by Adviesbeheer GIMV Life Sciences NV; and 477,704 shares held by Biotech Fonds Vlaanderen NV.
(2) As partial consideration under the Merger Agreement, holders of preferred stock of TPTX, Inc. also received warrants to purchase their pro-rata portion of 1,500,000 shares of the Issuer's common stock in exchange for their preferred shares. Warrants are held as follows: Warrant to purchase 286,897 shares held by GIMV NV; warrant to purchase 35,782 shares held by Adviesbeheer GIMV Life Sciences NV; and warrant to purchase 90,041 shares held by Biotech Fonds Vlaanderen NV.
 
Remarks:
This report is filed jointly by GIMV NV, Adviesbeheer GIMV Life Sciences NV, and Biotech Fonds Vlaanderen NV, as members of
 a Section 13(d) "group."  The reported securities are directly held by GIMV NV, Adviesbeheer GIMV Life Sciences NV, and
 Biotech Fonds Vlaanderen NV.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.